Dynavax's Hep B Vaccine Doesn't Pass Muster With FDA
Dynavax Technologies Corp. disclosed Monday that the U.S. Food and Drug Administration has balked at approving its Heplisav vaccine for hepatitis B because of safety concerns, but said it's optimistic about...To view the full article, register now.
Already a subscriber? Click here to view full article